Gritstone bio (GRTS)
(Delayed Data from NSDQ)
$0.48 USD
+0.02 (5.44%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.48 0.00 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.48 USD
+0.02 (5.44%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.48 0.00 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Analysts Estimate Gritstone Oncology, Inc. (GRTS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone Oncology (GRTS): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Gritstone Oncology Inc (GRTS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone Oncology Inc (GRTS) delivered earnings and revenue surprises of 14.46% and 5.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Oncology, Inc. (GRTS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Gritstone Oncology, Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.